LIMN down 26.83% intraday: Liminatus Pharma (NASDAQ) 09 Feb 2026 earnings ahead

LIMN stock opened the intraday session under pressure after a sharp sell-off, trading at $1.50 as of this update. The drop of 26.83% connects directly to volatile post-IPO trading and heavy volume of 62,812,368.00 shares. Investors now focus on the upcoming earnings announcement on 12 Feb 2026, seeking data on clinical progress and cash runway. We examine financials, technicals, and analyst context to frame likely market reaction and near-term scenarios for Liminatus Pharma, Inc. Class A Common Stock listed on NASDAQ in the United States.